Tech Company Financing Transactions
Trevi Therapeutics Funding Round
On 1/8/2015, Trevi Therapeutics received $15 million in funding from Solar Capital and Square 1 Bank.
Transaction Overview
Company Name
Announced On
1/8/2015
Transaction Type
Debt
Amount
$15,000,000
Round
Undisclosed
Investors
Solar Capital (Anthony Storino)
Square 1 Bank (Mara Huntington)
Proceeds Purpose
This financing is an important step for Trevi as we complete the funding for our ongoing clinical trials of Nalbuphine ER in uremic pruritus and prurigo nodularis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
195 Church St. 14th Floor
New Haven, CT 06510
USA
New Haven, CT 06510
USA
Phone
Website
Email Address
Overview
Trevi Therapeutics, Inc. is a drug development company founded in 2011 focused on developing T111 for the severe chronic itching condition known as pruritus. Pruritus is manifested in various dermatological, metabolic, hematologic and neuronal conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jennifer Good
Chief Financial Officer
Christopher Seiter
Chief Medical Officer
Thomas Sciascia
Vice President
Amale Hawi
VP - Bus. Development
Helena Brett-Smith
VP - Bus. Development
Yann Mazabraud
Browse more venture capital transactions:
Prev: 1/7/2015: Appconomy venture capital transaction
Next: 1/8/2015: Vidcaster venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs